Covalent conjugation of AZD8055 with unsaturated fatty acids for the development of mTOR nanoblockers: increasing the therapeutic efficacy of hepatocellular carcinoma treatment.
作者信息
Chau Wing Ki, Lee Terence Kin Wah
机构信息
Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong.
Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong; State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hong Kong.
出版信息
EBioMedicine. 2024 May;103:105113. doi: 10.1016/j.ebiom.2024.105113. Epub 2024 Apr 6.
Abstract
摘要
相似文献
1
Covalent conjugation of AZD8055 with unsaturated fatty acids for the development of mTOR nanoblockers: increasing the therapeutic efficacy of hepatocellular carcinoma treatment.用于开发mTOR纳米阻滞剂的AZD8055与不饱和脂肪酸的共价缀合：提高肝细胞癌治疗的疗效
EBioMedicine. 2024 May;103:105113. doi: 10.1016/j.ebiom.2024.105113. Epub 2024 Apr 6.
2
Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.化学工程化 mTOR 纳米颗粒阻滞剂增强抗肿瘤疗效。
EBioMedicine. 2024 May;103:105099. doi: 10.1016/j.ebiom.2024.105099. Epub 2024 Apr 10.
3
Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.苯磺酰胺衍生物作为对肝细胞癌具有体内疗效的强效PI3K/mTOR双重抑制剂的发现。
Bioorg Med Chem. 2016 Mar 1;24(5):957-66. doi: 10.1016/j.bmc.2016.01.008. Epub 2016 Jan 6.
4
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.PKI-587 单独及联合索拉非尼对肝癌干细胞增殖的抑制作用。
J Surg Res. 2013 Nov;185(1):225-30. doi: 10.1016/j.jss.2013.05.016. Epub 2013 May 25.
5
Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.设计、合成及新型 mTOR 和 HDACs 双重靶向杂合化合物用于肝癌潜在治疗的生物评价。
Eur J Med Chem. 2021 Dec 5;225:113824. doi: 10.1016/j.ejmech.2021.113824. Epub 2021 Sep 3.
6
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.靶向PI3K/AKT/mTOR和Ras/Raf/MAPK通路的PKI-587与索拉非尼协同抑制肝癌细胞增殖。
J Surg Res. 2012 Aug;176(2):542-8. doi: 10.1016/j.jss.2011.10.045. Epub 2011 Nov 21.
7
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.雷帕霉素联合硼替佐米对肝癌细胞及原位肿瘤模型的协同抗肿瘤作用。
BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.
8
Combination of Diosmetin With Chrysin Against Hepatocellular Carcinoma Through Inhibiting PI3K/AKT/mTOR/NF-кB Signaling Pathway: TCGA Analysis, Molecular Docking, Molecular Dynamics, In Vitro Experiment.染料木黄酮联合白杨素通过抑制 PI3K/AKT/mTOR/NF-кB 信号通路抗肝癌：TCGA 分析、分子对接、分子动力学、体外实验。
Chem Biol Drug Des. 2024 Oct;104(4):e70003. doi: 10.1111/cbdd.70003.
9
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.去γ-羧基凝血酶原通过激活Raf/MEK/ERK和PI3K/Akt/mTOR信号通路拮抗索拉非尼对人肝细胞癌的作用。
Oncotarget. 2016 Jun 14;7(24):36767-36782. doi: 10.18632/oncotarget.9168.
10
A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.一种老药的新用途：mTOR抑制剂雷帕霉素通过诱导细胞衰老增强氟尿嘧啶对肝细胞癌的疗效。
Cancer Biol Ther. 2008 Mar;7(3):397-8. doi: 10.4161/cbt.7.3.5871. Epub 2008 Mar 10.
引用本文的文献
1
Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.乙型肝炎驱动的肝细胞癌进展的关键癌基因和候选药物。
Discov Oncol. 2025 Feb 4;16(1):116. doi: 10.1007/s12672-025-01851-6.
本文引用的文献
1
Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.化学工程化 mTOR 纳米颗粒阻滞剂增强抗肿瘤疗效。
EBioMedicine. 2024 May;103:105099. doi: 10.1016/j.ebiom.2024.105099. Epub 2024 Apr 10.
2
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications.肝细胞癌的异质性：从机制到临床意义。
Cancer Gene Ther. 2024 Aug;31(8):1105-1112. doi: 10.1038/s41417-024-00764-w. Epub 2024 Mar 18.
3
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.T 细胞耗竭和驻留动力学为肝细胞癌的临床结局提供信息。
J Hepatol. 2022 Aug;77(2):397-409. doi: 10.1016/j.jhep.2022.02.032. Epub 2022 Apr 1.
4
Albumin-based nanostructures for uveal melanoma treatment.基于白蛋白的纳米结构用于葡萄膜黑色素瘤的治疗。
Nanomedicine. 2021 Jul;35:102391. doi: 10.1016/j.nano.2021.102391. Epub 2021 Mar 29.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
mTOR signalling and cellular metabolism are mutual determinants in cancer.mTOR 信号和细胞代谢在癌症中是相互决定因素。
Nat Rev Cancer. 2018 Dec;18(12):744-757. doi: 10.1038/s41568-018-0074-8.
7
Molecular therapies and precision medicine for hepatocellular carcinoma.肝细胞癌的分子治疗和精准医学。
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
8
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.靶向磷酸肌醇-3-激酶的超分子纳米颗粒克服胰岛素抵抗并发挥显著的抗肿瘤疗效。
Cancer Res. 2013 Dec 1;73(23):6987-97. doi: 10.1158/0008-5472.CAN-12-4477. Epub 2013 Oct 11.
9
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.AZD8055 在晚期实体瘤和淋巴瘤中的安全性、耐受性、药代动力学和药效学。
Br J Cancer. 2012 Sep 25;107(7):1093-9. doi: 10.1038/bjc.2012.368. Epub 2012 Aug 30.
10
Regulation of immune responses by mTOR.mTOR 对免疫反应的调节。
Annu Rev Immunol. 2012;30:39-68. doi: 10.1146/annurev-immunol-020711-075024. Epub 2011 Nov 29.
Zotero 插件